PRESS RELEASE | Basel, Switzerland, January 5, 2022

Versameb to Attend Biotech Showcase 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that it will be attending Biotech Showcase: The Investor Conference for Innovators on 10-12 January 2022. The Versameb team will be attending virtually.

Versameb’s pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its VERSagile platform.

If you would like to meet with the Versameb team virtually at the above event, please contact us at the details provided below. For more information, please visit us at www.versameb.com/upcoming-conferences-events/

Contact for media enquiries:

Versameb
Dr Klaas Zuideveld, CEO
ir@versameb.com

Optimum Strategic Communications
Mary Clark, Stella Lempidaki, Zoe Bolt
Tel: +44 (0)20 3882 9621
versameb@optimumcomms.com

DOWNLOAD PDF
– English